The Drum · Weekly AI news, freeSubscribe →
← All briefings
July 2026
The healthcare industry faced significant ethical and technological challenges in July 2026. Pope Leo XIV’s encyclical _Magnifica Humanitas_ provided much-needed guidance on the ethical use of AI, addressing concerns about equity, privacy, and compassionate care. Meanwhile, the European Medicines Agency (EMA) recommended revoking approval for Tavneos due to safety risks and data integrity issues, highlighting the ongoing scrutiny of new treatments. On a more positive note, the NIH’s All of Us program is leveraging EHRs to fill critical data gaps, while AI continues to play a growing role in advancing rare disease research.
The healthcare industry is increasingly turning to AI for both administrative and clinical applications, with payers like UnitedHealthcare and Zelis investing heavily in AI solutions.
Winners
Pope Leo XIV’s encyclical _Magnifica Humanitas_ for providing ethical guidance on AI
NIH’s All of Us program for integrating EHRs to enhance data richness
Under pressure
Tavneos, facing potential revocation by the EMA due to safety concerns
Eli Lilly, cutting 340B discounts and straining safety-net hospitals
How will healthcare organizations balance AI innovation with ethical considerations?
What long-term impacts will the reduction of 340B discounts have on safety-net hospitals?
© 2026 Cedar & Bloom. All rights reserved.
